Abstract: An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.

Abstract: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

Abstract: An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.

Abstract: The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.

Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.

Abstract: The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.

Abstract: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.

Abstract: The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.

Abstract: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.

Abstract: The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v 1a.

Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.

Abstract: The present invention relates to a variant of a mature polysaccharide lyase having a beta helix structure, wherein said variant comprises an N- and/or C-terminal truncation and consists essentially of at least 90% of the beta helix structure of the mature polysaccharide lyase.

Abstract: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

Abstract: A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.

Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.

Abstract: The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.

Abstract: Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.

Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.